Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Pharma Starts Clinical Trial for Hypertension Drug

publication date: Feb 16, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Pharma Holdings, Inc. has begun a clinical trial of a generic version of the hypertension drug Candesartan. China Pharma expects the trial will take 18 months to complete. Originally developed by Takeda Pharma of Japan together with AstraZeneca, Cardesartan is a front-line treatment for hypertension. It produced $2.5 billion in revenues worldwide during 2007. China Pharma is actively adding to its portfolio of generic drugs. More details...

Stock Symbols: (OTCBB: CPHI) (NYSE: AZN)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners